Early Fluid Resolution Predicts Faricimab Durability

Post hoc analysis suggests rapid retinal fluid resolution may help identify patients with nAMD who can maintain longer faricimab dosing intervals.

By
Conexiant News Staff
March 11, 2026
4 min

Conexiant

Objective:

To determine if early resolution of retinal fluid after initiating faricimab therapy can predict longer treatment intervals in patients with neovascular age-related macular degeneration (nAMD).

Key Findings:

265 out of 552 participants achieved resolution of intraretinal fluid (IRF) and subretinal fluid (SRF) within the first 12 weeks.
Patients with early fluid resolution were nearly twice as likely to receive every-16-week dosing compared to every-8-week dosing.
At week 112, those with early fluid resolution were more likely to remain on extended dosing intervals.

Interpretation:

Early anatomical response, indicated by fluid resolution, may serve as a predictor of treatment durability with faricimab, potentially allowing for longer intervals between treatments.

Limitations:

Findings are based on a post hoc analysis, which may limit the strength of the conclusions.
Further validation in prospective studies is needed to confirm the predictive value of early fluid resolution.